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Abstract 
PCBPl or poly (C) binding protein is a multifunctional protein, which belongs to the K 
homology domain superfamily. Its multiple functions include mRNA stabilization, 
translational regulation and transcriptional regulation, which have been found to affect 
the expression of the mu-opioid receptor gene. PCBPl's multiple functions may likely 
correlate to its various protein-protein interactions. We therefore examined its interacting 
protein(s) using a two-hybrid system by screening a cDNA library. After more than 1 
million clones were screened, a candidate interacting protein was identified as y- 
synuclein. The plasmid of this cDNA clone was purified and the interaction between 
PCBPl and y-synuclein was further confirmed using in viva validation with the bacteria 
system as well as using GST-pull down assay. 
To further examine if this physical interaction can take place in a mammalian cell system, 
several cell lines, including NMB (neuroblastoma), H292 (lung), HCTl16 (colorectal), 
HT29 (colorectal), T47D (breast), and Mcf-7 (breast), were used. Western blot analysis 
showed that these human cancer cell lines endogenously expressed PCBP1 and y- 
synuclein. The physical interaction of these two proteins was examined using cell Iysates 
from these cell limes by co-Immunoprecipitation (co-IP) and subsequentially via Western 
blot analysis. Results suggested a physical interaction between endogenous PCBPl and 
y-synuclein. To further investigate if these cell lines expressed the identical 7-synuclein, 
vii 
RT-PCR was performed using RNA h m  these cell l i e s  with a y-synuclein specific 
primer set. The PCR products were then subjected to DNA sequencing analysis. 
The obtained DNA sequences were then compared with the published cDNA sequence in 
GenBank. This comparison showed a consistent missense mutation at the C-terminus of 
y-synuclein. This mutation created a valine (non-polar) residue in the cells, whereas and 
a glutamic acid (acidic) residue in the database. A SNP database search was then 
performed to determine if this missense mutation was a SNP (single nucleotide 
polymorphism). A total of 53 SNPs were found for y-synuclein and one of them matched 
the mutation found. 
Since it is already known that PCBPl participates in the regulation of the mu-opioid 
receptor gene expression, and based on this study that PCBPl can physically interact with 
y-synuclein, the effect of this protein-protein interaction on MOR promoter was further 
investigated using a luciferase reporter gene assay with the mammalian expression 
plasmid containing each form of y-synuclein. Our preliminary results suggested that y- 
synuclein may be able to modulate MOR promoter activity, which will need to be f i d e r  
confirmed. In conclusion, PCBPl and y-synuclein physically interact in the mammalian 
system and this interaction may modulate PCBPl 's functional role. 
viii 
Introduction 
PCBPl belong to K Homology superfamily 
The K homology superfamily contains 3 KH (K homology) domains, which are nucleic 
acid binding domains. They contain two KH domains near the N-terminus and a third 
one near the C-terminus. The greatest sequential variance among the family lies in the 
domain between the second M domain and the third KH domain. This variable domain 
contains a NLS (nuclear localization signal), which gives this protein its ability to be 
shuttled between the nucleus and the cytoplasm (Berry et al., 2006). This superfamily 
contains two subcategories, the hnRNPs and the poly (C) binding proteins. PCBPl is a 
member of the K homology domain superfamily, and is a protein approximately 38kDa in 
size. It is also known as aCPl and hnRNP El. It is an ssDNA and RNA binding protein 
which binds to poly cytosine residues. PCBPl displays various physiological roles, 
including transcriptional regulation, translational regulation, and mRNA stabilization. It 
can form protein complexes and work in conjunction with other proteins to carry out 
various functions (Wang et al., 1999 and Rivera-Gina et al., 2006). 
mRNA Stabilization 
Binding of PCBPl protein can cause mRNA stabilization of many genes. Alpha-globin 
mRNA is an example. PCBPl, PCBP2 and PABP (ply A biding protein) form an 
alpha complex which binds to a sequence in the 3'UTR of alpha-globin mRNA. The 
binding of this ribonucleoprotein complex prevents mRNA decay and prevents 
deadenylation (Wang et al., 1999). Another example is that PCBPl along with hnRNP 
A1 and hnRNP K b i d  to a sequence at the 3' UTR of collagen mRNA, and this binding 
stabilizes its mRNA and acts as a positive effector of synthesis (Thiele et al., 2004). A 
similar effect is also seen in rain and gastrin genes (Lee et al., 2007 and Adam et al., 
2003). This increase in stability of mRNA and upregulation of protein synthesis caused 
by PCBPl can also be seen for erythropoietin and tyrosine hydroxylase, but in a hypoxia 
dependent condition by binding to the 3' UTR of their mRNA and regulating stability 
(Zhu et al., 2002). 
Transcriptional Regulption 
Another function of PCBPl is that it can serve as a transcriptional regulator. This 
function has been reported in two genes, eIF4E (eukaryotic translation initiation factor 4E) 
and MOR (mu-opioid receptor). PCBPl binds to a specific sequence in the promoter 
region of eIF4E which contains eIF4E basal element (4EBE) and increases transcription 
(Meng et al., 2007). PCBPl binds to a specific ssDNA sequence in the proximal 
promoter of mouse MOR gene and increases gene expression (KO et al., 2005). 
Translational Regulation 
PCBPl has also been reported as both a positive and negative translational regulator. 
The positive translational regulation has been reported in the c-myc gene. The proto- 
oncogene c-myc contains an internal ribosome entry segment (IRES) at its S'UTR. 
PCBPl, PCBP2, and hnRNP K bind to c-myc's IRES mRNA and this binding leads to 
IRES mediated translation (Evans et al., 2003). Negative translational regulation has 
been shown in the 15-lipoxygenase (LOX) gene. PCBPl along with PCBP2 and hnRNP 
K form a complex and bind to the differential control element @ICE). The differential 
control element is a CU rich repeated motif at the 3'UTR. The binding of this protein 
complex prevents the 60s and 40s ribosome subunits from joining and forming the 80s 
ribosome at AUG sequence. Without the joining of the subunits, translation cannot occur 
(Ostarek et al., 1997). A similar effect is also reported in the A2 response element 
(MRE), in which PCBPl and hnRNPA2 together bind to A2RE. With this binding, the 
translation of A2RE RNA is prevented (Kosturko et al., 2006). 
Other functions 
PCBPl has also been found to affect the cytoskeletal composition of neurons. PCBPl, 
PCBP2, and hnRNP K bind to the low, middle and high molecular mass neurofilament 
subunit proteins. These subunits will then co-polymerize and form neurofilaments 
(Thyagarajan et al, 2008). PCBPl has also been found to act as a chaperone in the 
delivery of iron to femtin, an iron storage protein (Shi et al., 2008). 
To further understand PCBPl's different functional roles, our laboratory investigated this 
aspect by examining the protein-protein interactions using the two-hybrid system. This 
system employed two vectors, a bait protein containing vector and the other vector 
containing a cDNA library for screening candidate clone(s) of PCBP1 interacting protein. 
PCBPl was used as the bait protein to screen its interacting protein(s) from a human 
brain cDNA library. Over 1 million clones were screened, and y-synuclein was found to 
be a candidate interacting protein. In viw validation was performed using the purified 
plasmids via co-transformation. The confirmation of in vitro physical interaction was 
also obtained using the GST-pull down technique (Lab unpublished data). 
Synuelein Family and y-synuclein 
The synuclein family contains a, $, and y synuclein. The synuclein family has high 
amino acid sequence homology. Sequence comparisons show that a to $ has 62% 
identity and 79% homology, a to y has 50% identity and 74% homology, and j3 to 7 has 
47% identity and 66% homology. The highest divergence of amino acid sequence within 
the synuclein family is found in the C-terminus (Sung et al., 2006). These proteins have 
been shown to possess the ability to aggregate, and each member possesses different 
propensities for aggregation. The a-synuclein has the greatest propensity, and 7 closely 
resembles it in its h e  state residual secondary structure. The j3-synuclein possesses the 
least propensity for aggregation and it has been reported to protect a from aggregation in 
vitro (Sung et al., 2007). At the current stage, the functions of these three proteins have 
not been well understood. 
The y-synuclein is also known as breast cancer specific gene l(BCSG1) and persyn, and 
is a small intracellular protein about 13kDa in size (Buchman et al., 1998). It locates at 
chromosome 10q23, and contains 5 exons coding for 127 amino acids (Lavedan et al., 
1998). It was originally found in the nervous system and considered to be a neural 
protein (Malatynska et al., 2006). The y-synuclein has also been found to be over- 
expressed in many malignancies and considered a bio~narker. It is related to 
newodegenerative disorders including, Parkinson's disease, Alzheimer's disease, 
Amyotrophic lateral sclerosis, Lewy body disease, and vascular dementia (Mukaetova- 
Ladinska and Lincoln et al., 1999). In addition, it has been reported recently highly 
expressing in Retinal Ganglion Cells (RGCs) (Swgucheya et al., 2008). 
Presence of 7-synuclein in Nervous System 
The y-synuclein was initially found in nervous system tissue and is therefore considered 
to be a neuronal protein (Zhao et al., 2006). The mRNA levels of synuclein-a, fl, and y 
were quantified in different brain regions at different ages of mice. The hippocampus, 
stria-, cortex, and cerebellum were the regions used. The rank order of mRNA for y- 
synuclein was hippocampus=striatum>cortex~erebellum. The rank order was different 
for both synuclein a and fl. The levels varied in each region depending on mouse age. 
For example, y-synuclein levels increased significantly only in the cerebral cortex from 5 
d to 1 mo of age, but levels in the cerebellum were very high at 5 d and significantly 
reduced at 1 mo. The different patterns and dynamics of mRNA levels of this family of 
proteins as the mice aged suggests that they may play a role in development and aging 
(Malatynska et al., 2006). 
In addition, a and y synuclein proteins have also been found elevated in cerebral spinal 
fluid (CSF) in elderly individuals with Alzheimer's disease, Lewy body disease, and 
vascular dementia when compared to normal controls. y-synuclein had greater elevation 
in CSF of patients with Lewy body disease. Elevated synuclein -a and y were found in 
CSF of patients in Braak stage 111 and onward and then remained stable until Braak stage 
N (Mukaetova-Ladinska et al., 2008). Braak stages represent a system used to classify 
Alzheimer patients' stage in the disease. They span from stage I-VI and represent the 
level of impairment in the patient. Stage I representing no impairment and stage VI 
representing severe decline 
(http://www.alz.org/alzheimersTSdiseaseSeaSestagesSoff alzheimersap). Since y-synuclein is 
expressed in nervous tissue and found to be highly expressed in nervous tissue of patients 
with neurodegenerative disease, its DNA sequence was screened to search for possible 
polymorphism mutations linked with neurodegenerative diseases states, such as 
Parkinson's disease and ALS. Polymorphisms have been reported but so far none of 
them is found to be d i i t l y  correlated with the disease state (Lincoln et al., 1999). 
Presence of *y-synuclein in Cancers 
Up to now, y-synuclein has been found in many different types of cancers, including 
pancreatic adenocarcinoma, uterine papillary serous carcinoma, breast, colorectal, 
ovarian, lung, liver, gastric cancer, and bladder cancer (Li et al., 2004, Huh et al., 2009, 
Hibi et al., 2009, Morgan et al., 2009, Liu et al., 2007, Zhao et al., 2006, Yanagawa et al., 
2004 and Dokun et al., 2008). Its expression level is correlated to a number of facts 
including cancer stage, lymph node involvement, metastasis, and penneural invasion. 
For example, in a study using 93 breast carcinoma samples y-synuclein expression was 
seen in 36% of all the samples, 81% of the samples from stage IIVIV, and 15% of the 
samples in stage MI. Cancer stages depend on five factors, which include location of the 
primary tumor, tumor size and number of tumors, lymph node involvement, cell type and 
tumor grade, and the presence or absence of metastasis 
(http://www.cancer.gov/cancertopics/factsheeetectiodstaging). No y-synuclein 
expression was seen in normal breast tissue. It was also found that y-synuclein presence 
in the primary tumor signified lymph node involvement and metastasis. Again, the 
presence of y-synuclein in breast cancer patients had a significantly shorter disease free 
survival and increased probability of death (Wu et al., 2007). 
The trend of 7-synuclein expression and advanced stage cancer is also found in liver and 
gastric cancer as well. In liver cancer samples y-synuclein was expressed in 67% of all 
samples, 5.3% of stage I samples, 88% in stage IIIIIV samples, and 100% on metastasis 
samples (Zhao et al., 2006). In gastric cancer samples y-synuclein was expressed 40% in 
primary cancers, 51% in primary cancers with lymph node metastasis, 26% in gastric 
cancer without lymph node involvement, 48% in stage 11-IV samples, and 27% in stage I. 
y-synuclein was not expressed at all in benign tissue. These also suggest that there is a 
higher y-synuclein expression in advanced cancer stages and metastasis phase (Yanagawa 
et al., 2004). 
Using a pancreatic cell line, proteomic and transcriptomic analyses confirmed that y- 
synuclein is the only upregdated protein found in p e ~ e u r a l  invasion, which is the 
growth of tumor along nerve branching, providing a path for tumor invasion into new 
tissue. The expression of y-synuclein was found correlated to perineural invasion and 
lymph node metastasis, diminished overall survival, and the strongest negative indicator 
of disease free survival. Knockdown y-synuclein expression significantly decreased 
perineural invasion and liverllymph nodes metastasis (Hibi et al., 2009). 
In conclusion, y-synuclein is highly expressed in the advanced cancer stages and not 
expressed at all in normal tissue, except neuronal cells. Therefore, y-synuclein may be 
used as a biological biomarker for these cancers. 
Regulation of y-synuclein expression by DNA Methylation 
When analyzing the promoter region of y-synuclein in cancer cell lines where it is 
overexpressed, this region was found to be hypomethylated at CpG islands. Exogenous 
overexpression of DNMT3B, a DNA methyl transferase, causes suppression of y- 
synuclein mRNA and protein expression in a lung cancer cell line. This caused induction 
of de novo methylation of y-synuclein CpG island. When siRNA was used to knock- 
down DNMT3B there was an increase in y-synuclein expression. Carcinogens, such as 
cigarette smoke extract (CSE), have been found to induce down regulation of DNMT3B 
and lead to y-synuclein increased expression (Liu et al., 2007). 
Similar results were also found in breast and ovarian cell lines, as well as using samples 
f h m  the patients' bladder, gastric, and liver samples (Gupta et al., 2003, Zhao et al., 2006, 
Yanagawa et al., 2004 and Dokun et al., 2008). These data have given some insight on 
how to tackle the problems that y-synuclein's expression causes. Since a proposed cancer 
treatment was the use of 5-aza-2'deoxycytidiie to prevent the methylation of tumor 
suppressor genes, it's now found to activate prometastatic genes, y-synuclein (Ateeq et al., 
2008). In conclusion, y-synuclein found in cell lines in which it is overexpressed is 
correlated to a hypomethylated promoter region. 
Rationale 
From above, both PCBPl and y-synuclein have been reported to play various mles in the 
cell. Up to now there is no report in the literatures showing the interaction of these two 
proteins. Therefore, this study is to examine their physical interaction in vivo using 
mammalian system, and explore the possible functional role of this interaction. 
Materials and Methods 
Cell Culture 
T47D, H292, Mcf-7, HCTl16 and HT29 cell lines were obtained from ATCC. NMB (KO 
et al., 2005), T47D, and H292 cell lines were maintained in Roswell Park Memorial 
Institute Medium (RPMI). Mcf-7 cell line was maintained in Dulbecco's Modified 
Medium (DMEM). HCTl16 and HT29 cell lines were maintained in McCoy's media 
Ail medium were supplemented with 10% Fetal Calf Senun and all cell limes were 
maintained at 37°C in a 5% COz incubator. 
Lowry Assay 
Using bovine serum albumin as a standard, protein concentrations were determined using 
Lowry assay. Lysate samples were incubated at room temperature with solution C 
(1.8mM Na2CO3,98mM NaOH, 0.95mM sodium potassium tartarate, and 0.4rnM CuS04 
5Hz0) for 10 minutes and further incubated with IN Folim Ciocalteu's Phenol reagent for 
30 minutes. The samples were examined at 660nm using colorimetry to determine the 
protein concentration. 
Western Blot Analysis 
Samples were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then electrotransferred to phenylethylsulfonyl fluoride 
(PVFD) membranes. AAer a series of washes in .l% and .3% TTBS (Tween-20 Tris 
Buffered Saline), the membrane was probed with a specific antibody. The signals were 
detected using an enhanced chemiluminesence detection system (Amersharn Biosciences). 
The anti-PCBP1 and y-synuclein antibodies were purchased from Santa Cruz 
Biotechnology. 
Co-Immunoprecipitation 
Cell lysate was first incubated with anti-PCBP1 antibody or negative control and then 
added Protein G-agarose beads. The beads were washed with PBS and then the 
immunocomplex was eluted using treatment buffer containing SDS. 
RNA Isolation 
RNA from cells were extracted using Tri-Reagent fmt and then with chloroform. The 
mixture was subjected to centrifugation. The top phase containing total RNA was 
removed. RNA was precipitated using isopropanol. 
RT-PCR 
F i t  strand cDNA was synthesized using total RNA and the random primer, in the 
presence of reverse transcriptase. Amplification was performed as 50 minutes at 37'C 
and 15 minutes at 70°C. PCR amplification of cDNA was performed as 1 minute at 95'C, 
35 seconds at 68"C, and 35 seconds at 72'C for 32 cycles. The y-synuclein primers were 
as follows: upper, S'GTGGAGGAGGCGGAGAACATC :lower, 
3'CCTCTAGTCTCCCCCACTCTG. 
pCR2.1 Cloning 
PCR product was cloned into with the cloning site of pCR2.1 vector, purchased from 
Invitrogen . E. coli competent cells were then transformed with the ligation mixture 
using the heat shocking method. The transformants were then selected using ampicillin 
LB agar plates. 
Small Scale Plasmid PuriTcation 
Plasmids were extracted from cultures using Qiaprep Miniprep Kit from Qiagen. 
Cultures were centrifuged and pellets were resuspended in P1 (50mM glucose, lOmM 
EDTA, pH 8.5,25mM Tris HCI, pH 8). They were lysed using Lysis Buffer P2 (0.2M 
NaOH, 1% SDS), and then neutralized by adding Neutralizing Buffer N3 (5M potassium 
acetate, glacial acetic acid). The plasmids are separated by centrifugation and applied to 
Qiaprep spin column, which was washed with Buffer PB and PE. The plasmids were 
eluted by Buffer EB (1OmM Tris HCI, 1mM EDTA, pH 8.4). 
Large %ale Plasmid Purification 
Bacteria cultures were grown overnight at 37°C. The plasmids were extracted using 
Qiagen Plasmid Maxiprep Kit from Qiagen. Bacteria cultures were centrifuged and the 
pellet was resuspended in lOmL of Buffer Pl(50mM glucose, 1OmM EDTA, pH 8.5, 
25mM Tris HCl, pH8). The bacteria suspension was then lysed by adding 10 mL of 
Lysis Buffer P2 (0.2M NaOH, l%SDS), which were further neutralized by addiig 10 mL 
of Neutralizing Buffer P3 (5M potassium acetate, glacial acetic acid). The mixture was 
centrifuged at 15,000 rpm. The supernatant was loaded to a Qiagen-tip column, which 
was then washed with Buffer QC. The plasmid was eluted using Buffer QF, and it was 
precipitated using isopropanol precipitation method. 
Transfection and Reporter Gene Assay 
NMB cells were transfected using lipofection method with various concentrations of 
plasmids containing pcDNA3?-synuclein, pcDNA3-SNP y-synuclein, or blank vector 
(pcDNA3), individually. The pGL3 plasmid containing the luciferase reporter gene 
driven by the human MOR promoter was also added in each sample. The pCHl10 
plasmid was included as an internal standard. Twenty four hours after transfection, cells 
are harvested and lysed. The luciferase activity was then measured using luciferase 
reagent (Promega) with a iuminometer (Berthold). 
Results 
Vedication of different cell Lines expressing y-synuclein and PCBPl endogenously 
The interaction between PCBPl and y-synuclein has been examined via in vivo validation 
using the two-hybrid system as well as using the GST pull-down assay (lab unpublished 
data). To further determine if this interaction also occurred in the mammalian system, the 
human cell model system was selected. The literatures were. searched first. Based on 
published data, a total of six cell lines were chosen, including neuroblastoma (NMB) (lab 
data), lung cancer (H292) (Liu H et al., 2007), breast cancer (T47-D & Mcf-7) (Liu C et 
al., 2008 and lab data), and colorectal cancer (HCT-116 62 HT29) (Liu C et al., 2008), 
which were reported to express y-synuclein endogenously. Therefore, the endogenous 
expression of both PCBPl and y-synuclein was examined first using Western blot 
analysis with cell lysates &om these cells and anti-PCBP and anti-ysynuclein antibodies. 
Although the monomer form of y-synuclein is 13kDa, it is reported to have a high 
tendency to form aggregates (Sung et al., 2007). As in Fig. 1, Western blot analysis 
showed the aggregated forms of y-synuclein observed in the different cell lines. In 
Figure 2 results showed PCBPl expression in all mammalian cell lines. 
Figure 1 : Examination of y-synuclein expression using six cell lines. 
Endogenous expression of y-synuclein was determined via Westem Blot analysis, using T47D, H292, 
HT29, HCTl16, NMB and Mcf-7 cell lysate and anti-y-synuclein antiidy. Arrows indicate the positions 
of protein markers. 
Mcf-7 NMB 
Figure 2: Examination of PCBPl expression using six cell lines. 
Endogenous expression of PCBPl was determined via Western Blot analysis, using T47D, H292, HT29, 
HCTl16, Mcf-7, and MB cell lysate and anti-PCBP antibody. Arrows indicate the positions of protein 
markers. 
Determination of physical interndon using mammalian cell lines 
To examine the PCBPl and y-synuclein interaction in the mammalian cell system, co- 
immunoprecipitation was performed using a PCBPl specific antibody. This technique 
can be used to determine the protein-protein interaction, for if an endogenous protein- 
protein interaction exists, then the PCBPl antibody will pull down PCBPl and its 
interacting proteins. The immunoprecipitated complex will then be able to be examined 
using SDS-PAGE and Western Blot analysis. 
Cell lysate was incubated with anti-PCBPlantibody and without antibody separately as a 
negative control, and then protein G agarose beads were added. The co- 
immunoprecipitants were subjected to SDS-PAGE and then Western Blot analysis. In 
figure 3A, NMB cell lysate was used, and in figure 3B, H292 cell lysate was used. The 
blots were probed with anti-synuclien antibody and re-probed with anti-PCBP1 antibody 
to confirm the pull-down of PCBP protein. A y-synuclein band was seen showing it was 
pulled down (shown in Figures 3A and 3B), and also a PCBPl band was seen showing 
pull down occurred (data not shown). No bands were seen for cell lysates incubated with 
no antibody. These results show that when PCBPl is pulled down, y-synuclein is pulled 
down as well, suggesting that a physical interaction between PCBPl and y-synuclein is 
taking place endogenously in these mammalian cell line. (Figure 3) Also, the negative 
control results validate the co-irnrnunoprecipitation results by showing that without 
antibody no pull-down occurs. 
This procedure was performed using 6 different cell lines, Mcf-7 and T47-D (breast 
cancer cell lies), HT29 and HCTl16 (colorectal cancer cell lines), H292 (lung cancer 
cell line) (Fig 3B), and NMB (neuroblastoma) (Fig 3A). The same pattern of protein- 
protein interaction was observed in all cell lines. 
Control C0.P Cootrol Co-IP 
y-synwlein y-synuckin 
A. 3 9 m  B. -38- 
Figure 3: Co-Immunoprecipitation using mammalian cell lines 
Figw A shows resulls using NMB mll lysalr: and Figw B shows resulls using HZ92 mll lywe. The 
Western blot analysis was performed using y-synuclein antibody or without antibody. The band of y- 
synuclein appeared m both figures, showing that the PCBPl antibody pulled down y-synuclein with the 
PCBP1. Lane 1 is the negative control. Lane 2 is the Co-IP using PCBPl antibody. 
Examining the cDNA sequence of the 7-synuclein in mammalian cell Lines 
To further confirm the existence of y-synuclein in these cell lines, the DNA sequences of 
y-synuciein were examined using RT-PCR by using y-synuclein specific primers. The 
RNA was isolated from NMB, H292, HT29, HCTl16, Mcf-7, and T47D cell lines. RT- 
PCR was performed and the sizes of PCR products verified using electrophoretic analysis 
(Figure 4). RT-PCR products were then cloned into pCR2.1 vector. Positive clones 
containing the PCR products were screened by restriction enzyme digests followed by 
electrophoretic analysis (Figure 5). The plasmids containing the PCR products were then 
subjected for DNA sequencing. The DNA sequencing results showed a consistent 
missense mutation at the C-terminal, when compared with GenBank's published cDNA 
sequence. The mutation was a TIA mutation causing a valine residue to become a 
glutamic acid residue 
4OObps 
Figure 4: Electrophoretic analysis of PCR products from HCT 116 cell 
GA isolation 60m&ll lysate was performed followed by RT-PCR to amplify the cDNA sequence by 
using specific primers for ysynuclein. Agamm gel electrophoresis of the PCR product was performed to 
verify. A band is seen at approximately 400bps corresponding to the 386bp 7-synuclein cDNA sequence. 
Lane 1 is the lOObp ladder. Lanes 2-4 represent HCT116 cell lines endogenous cDNA amplified using RT- 
PCR. 
cell line 
RT-PCR products w-& ligated with $R2.1 vector, hansfomed&d screened. To ensure positive clones 
contained the y-synuclein insert, EcoRl digests followed by agarose gel electrophoresis was perfomed. An 
insert band is indicated by arrow and a band is seen at a much higher size represen!ing the cut pCR2.1 
vector. Lane 1 is the lOObp ladder. Lanes 2-4 represents HCT 116 cell l i e  endogenous cDNA cloned into 
pCR2.1 vector. 
SNP of 7-synuclein 
Multiple SNPs (single nucleotide polymorphisms) are available on NCBI's SNP database. 
A database search was then performed for y-synuclein and a total of 53 SNPs were found 
(Table l), including the missense mutation found expressed endogenously in the 
mammalian cell lines. Below is a table listing the reference number and sequence of all 
the SNPs found in the database for y-synuclein with the SNP matching the missense 
mutation highlighted. 
Table 1 : SNPs of y-synuclein 
A total of 53 SNPs were found for y-synuclein in NCBI's SNP database. L i e  18 is the mutation matching 
our sequence analysis. 
Exploring the functional role of PCBPl and 7-synuclein interaction on the MOR 
promoter activity 
Since the above data showed that PCBPl and y-synuclein physically interacted 
endogenously in the mammalian system, a possible functional role of this interaction can 
be examined using the reporter gene assay. Since it is known that PCBPl can regulate 
the expression of the mu-opioid receptor gene, this technique can therefore be used to 
examine if y-synuclein has any effect on MOR promoter activity via its interacting with 
PCBPl. Co-transfection was performed using .5, 1, and 2ug of pcDNA3-SNP or DB 
plasmid or blank vector as a control, along with the luciferase reporter plasmid containing 
the human MOR promoter. pcDNA3-SNP plasmid contains the DNA sequence of y- 
synuclein matching the SNP form and the pcDNA3-DB plasmid contains the DNA 
sequence of y-synuclein matching the GenBank database fom. The reporter activity 
using pcDNA3 blank vector is defined as 100%. The preliminary test (Figure 6) showed 
the pcDNA3-SNP plasmid caused a slight expression increase at Sug and an expression 
decrease to about 800! of the control when the concentration was increased, and the 
pcDNA3-DB plasmid caused an expression increase at Sug and an expression decrease 
to about 70% of the control when the concentration was increased. This shows that the 
interaction between PCBPl and y-synuclein may affect MOR promoter expression; 
however, more experiments need to be performed to further investigate. 
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Figure 6: The effects of overexpressing SNP and DB forms of y-synuclein on the human 
MOR promoter activities. 
The black bars wpmsaits data ob&ined h m  mnpks overcxpmwd with the DB form of ysynuclein. The 
light grey bars represent the data obtained &om samples overexpressed with the SNP form of y-synuclein. 
Tbe black and grey spotted bars represent the data obtained from samples overexpressed with blank vector. 
Discussion 
Protein-protein interactions affect many things inside the cell, including the change of a 
protein's function. This concept has been reported for PCBPl, for it b i d s  along with 
hnRNP K and PCBP2 to c-myc mRNA causing positive translational effect (Evans et al., 
2003), while when it b i d s  along with hnRNP A1 and hnRNP K to collagen mRNA it 
causes mRNA stabilization (Thiele et al., 2004). In this present study one more PCBP 
interacting protein, y-synuclein, was discovered by showing that y-synuclein and PCBPl 
physically interact using six different mammalian cell lines found to endogenously 
express both proteins via a literature search and Western Blot analysis. Co- 
immunoprecipitation followed by Western Blot analysis demonstrated this interaction. 
When analyzing the Western Blot data obtained after co-immunoprecipitation, it is seen 
that PCBPl only interacts with a form of y-synuclein approximately trimer in size, 
approximately 39kDa. 
The monomer protein of y-synuclein is 13kDa in size, but Western Blot analysis of 
mammalian cell l i e  lysate showed proteins of multiple sizes. There are possible reasons 
for these results. First, this protein has a high propensity for aggregation (Sung et al., 
2007). The higher molecular weight protein expressed may be a multimer of the protein. 
Second, the other possibility is that the higher molecular weight is due to post 
translational modifications. Third, y-synuclein may be also interacting with another 
protein and form a protein complex. y-synuclein has been proven to interact with PCBPl 
in this study, but it has also been shown to act as a chaperone protein, biding along with 
Hsp70 and Hsp90 to ER-a (estrogen receptor a) in the unliganded state in breast cancer. 
This binding enhances the high affinity ligand-binding capacity of the receptor (Jiang et 
al., 2004). Since it is know that y-synuclein interacts with multiple proteins, the higher 
molecular weight seen may be due to a protein complex. Any of these possible 
explanations for the higher molecular weight form seen can affect how the protein 
interacts. 
To M e r  validate y-synuclein in these cell l ies,  its cDNA was analyzed and a 
consistent missense mutation was found when compared with GenBank's published 
cDNA sequence, which coded for a valine residue versus a glutamic acid residue. This 
missense mutation was found in a SNP database search, with a total of 53 SNPs for y- 
synuclein. Since the synuclein family has been found to play a role in neurological 
disorders, this mutation has been previously investigated using DNA screening and their 
results indicates that this SNP (glutamic acid residue instead of valine residue) has no 
direct correlation to the disease in Alzheimer's patients (Luedecking et al., 1999) and no 
correlation was found for any known polymorphisms for Parkinson's disease or 
amyotrophic lateral sclerosis (ALS) (Flowers et al., 1999). However, having a non-polar 
residue versus a poladacidic residue, may affect the proteins 3D structure as well as 
possible its biding activity. 
To further investigate the role of PCBPl and y-synuclein's interaction, the luciferase 
reporter gene assay was performed to see how their interaction may affect MOR 
promoter activity via using both the database and SNP form of y-synuclein. Preliminary 
data implicated that the interaction between y-synuclein and PCBPl may possibly affect 
MOR promoter activity, and the database. form of y-synuclein may have a slight stronger 
effect than the SNP form. However, this experiment needs to be repeated and confirmed. 
PCBPl and y-synuclein have been shown to interact with each other as well as interact 
with other proteins separately. It is a possibility that PCBPl and y-synuclein's interaction 
with each other may display different functional role+) for each of them interacts with 
the other protein@). For example, the interaction between PCBPl and y-synuclein may 
affect y-synuclein's role as a chaperone protein in the biding to the unliganded state of 
the ERa. Experiments would need to be performed to investigate this, such as co- 
irnmunoprecipitation and confocal microscopy to see protein-protein interactions. 
In conclusion, this study has identified a physical protein-protein interaction between 
PCBPl and y-synuclein endogenously amongst six mammalian cell lines expressing both 
proteins. To W e r  investigate this interaction more functional assays, such as the 
luciferase reporter gene assay need to be repeated. Also, immunofluresence followed by 
confocal microscopy should be performed to further analyze the interaction as well as the 
location inside the cell in which it takes place. Using truncated cloned forms of both 
PCBPl and y-synuclein to screen to find the location on each protein in which this 
interaction takes place should be performed to give more insight on how this interaction 
works. 
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